Premium
Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice
Author(s) -
Yoshizawa Kazumi,
Arai Narumaki,
Suzuki Yukina,
Nakamura Toka,
Takeuchi Kota,
Sakamoto Reinii,
Masuda Ritsuko
Publication year - 2018
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.22056
Subject(s) - sodium channel , nociception , sodium channel blocker , pharmacology , mexiletine , analgesic , anticonvulsant , chemistry , anesthesia , ethosuximide , agonist , licking , medicine , sodium , epilepsy , receptor , organic chemistry , psychiatry
An important role of voltage‐gated sodium channels (VGSCs) in many different pain states has been established in animal models and humans wherein sodium channel blockers partially ameliorate pain. However, behavioral tests for screening analgesics that exhibit pharmacologic action by acting on VGSCs are rarely reported, and there are no studies on antinociception using veratrine as a nociceptive agent. The aim of the present study was to examine the amount of nociceptive behavior evoked by subcutaneous administration of veratrine into the hind paw and investigate whether veratrine can be used as a VGSC agonist to test the pharmacological properties of candidate analgesics via sodium channel blockade. We report for the first time that intraplantar injection of veratrine produced a reproducible nociceptive response in mice. Furthermore, several sodium channel blockers, namely carbamazepine, valproate, mexiletine, and the selective Nav1.7 inhibitor PF‐04856264, but not flecainide or pilsicainide, reduced veratrine‐induced nociception. In contrast, calcium channel blockers gabapentin and ethosuximide did not change veratrine‐induced nociception. The veratrine test in mice might be a useful tool, at least in part, to evaluate the potential analgesic effect of sodium channel blockers.